

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 30274

**Title:** Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease

**Reviewer's code:** 00159305

**Reviewer's country:** Romania

**Science editor:** Jing Yu

**Date sent for review:** 2016-09-26 16:50

**Date reviewed:** 2016-10-31 02:46

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

To the Authors, 1. There are several grammar/spelling English errors (i.e., page 11, second paragraph, line 2: "CD may be altering.."). Please, makes corrections. 2. Please, re-write and make it clear the last phrase pages 13-14: "We used the CDI...follow-up". 3. The core-tip is lacking. Please, write it. 4. Discussion. How can the results of your study be applied in clinical practice; please, make detailed comments in Discussion section. 5. References in text: please use brackets. 6. . References: please, write all the references according to the Format for references (PMID and DOI requirements, the name of the first author should be taped in bold-faced letters, the. family of all authors should be typed with the initial letter capitalized etc.).

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 30274

**Title:** Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease

**Reviewer's code:** 00505564

**Reviewer's country:** United States

**Science editor:** Jing Yu

**Date sent for review:** 2016-09-26 16:50

**Date reviewed:** 2016-11-26 08:57

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

Oh et al. analyzed clinical correlations of infliximab trough levels and antibodies to infliximab in Asian/Korean patients with Crohn's disease. They enrolled 138 patients with Crohn's disease (84 with quiescent and 54 with active disease) and observed, indifference in patients with and without concomitant immunomodulator use. However, in patients with quiescent vs. active diseases, the median IFX-TLs were 1.423 µg/mL and 0.163 µg/mL, respectively ( $p < .001$ ) and the median ATI levels were 8.064 AU/mL and 11.209 AU/mL, respectively ( $p < .001$ ). In the ATI-negative and -positive groups, the median IFX-TLs were 1.415 µg/mL and 0.141 µg/mL, respectively ( $p < .001$ ). The paper concludes that IFX-TL/ATI levels were well correlated with the clinical activity in Korean Crohn's disease patients and that the findings support the usefulness of IFX-TLs/ATIs in treating Crohn's disease patients receiving IFX in clinical practice. The paper is attractive. There are some grammatical errors that need attention. My suggestion to the authors is that they should have someone with English as first language to help out and should follow the format guidelines stipulated by the journal.